ERBB2 and breast carcinoma: A further significant improvement of pathological complete response rates after neoadjuvant treatment of HER2 positive breast cancer has been observed recently, when the dimerization inhibitor pertuzumab was added to trastuzumab and chemotherapy (pathological complete response rates 29% versus 45%) [12].